The Committee for Medicinal Products for Human Use of the European Medicines Agency has given a positive opinion on the use of Bortezomib in mantle cell lymphoma . This new indication covers the use of bortezomib, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone , for the treatment of adult patients with previously untreated MCL who are unsuitable for hematopoietic stem cell transplantation.
http://ift.tt/1GCw9C7
http://ift.tt/1GCw9C7
No comments:
Post a Comment